Q ed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium loremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. …

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it
The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019
PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…
Our team focuses on implementing basic management structures into your business.
This one is about streets and exterior design trends for those who like it unusual.

The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a list of…

Q ed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium loremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. …

Q ed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium loremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. …

Shots:
May all the sweet magic of Christmas conspire to gladden your heart and fill every desire
We would like to Thank You all for your sincerest appreciation and concern as well as your trust you have shown to us
Wishing you a season of joy and looking forward to continued success in 2020 and…

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year's record of approvals. However, there is a significant…

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' possessing similar…